Published in Thromb Res on November 28, 2005
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (2006) 3.25
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology (2014) 2.12
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med (2007) 1.63
Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines. Reg Anesth Pain Med (2016) 1.60
Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. Thromb Haemost (2012) 1.37
Cervical artery dissection: pathology, epidemiology and management. Thromb Res (2009) 1.33
Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke (2010) 1.19
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol (2009) 1.11
Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.11
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res (2011) 1.03
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood (2010) 0.97
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost (2008) 0.93
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol (2013) 0.92
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther (2005) 0.92
Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. Thromb Haemost (2003) 0.89
Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol (2009) 0.87
Thrombosis is associated with inferior survival in multiple myeloma. Haematologica (2012) 0.86
Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol (2013) 0.84
Respiratory review of 2013: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2013) 0.82
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thromb Haemost (2012) 0.81
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis (2007) 0.81
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost (2010) 0.81
Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thromb Haemost (2012) 0.81
Acquired hemophilia masked by warfarin therapy: report on two cases. Blood Coagul Fibrinolysis (2003) 0.80
Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. J Thromb Thrombolysis (2015) 0.80
Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus. J Infect Dis (2003) 0.80
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost (2016) 0.80
Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. Semin Hematol (2011) 0.80
Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. J Thromb Thrombolysis (2014) 0.80
Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study. Thromb Res (2012) 0.79
High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thromb Haemost (2013) 0.79
A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thromb Haemost (2010) 0.79
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost (2013) 0.78
Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. Curr Med Res Opin (2006) 0.78
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thromb Haemost (2005) 0.77
Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. Pharmacotherapy (2013) 0.77
Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis? Blood Coagul Fibrinolysis (2012) 0.77
Bile acids and coagulation factors: paradoxical association in children with chronic liver disease. Eur J Gastroenterol Hepatol (2013) 0.77
Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V. Haematologica (2008) 0.76
Recombinant FVIIa in children with liver disease. Thromb Res (2005) 0.76
NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study. J Clin Pharmacol (2007) 0.76
Extended anticoagulation in venous thromboembolism. N Engl J Med (2013) 0.76
Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. Semin Thromb Hemost (2009) 0.76
Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol (2014) 0.76
Response to Dr Junqueira. Chest (2013) 0.75
The onerous task of comparing treatments in inhibitor patients. Thromb Haemost (2007) 0.75
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. J Popul Ther Clin Pharmacol (2013) 0.75
Reply to Dr Lessire et al. Reg Anesth Pain Med (2016) 0.75
A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran. Semin Vasc Med (2005) 0.75
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost (2015) 0.75
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Br J Haematol (2006) 0.75
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost (2016) 0.75
Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism. Hematol J (2002) 0.75
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost (2016) 0.75
The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. Thromb Haemost (2016) 0.75
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II. Thromb Haemost (2017) 0.75
Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost (2016) 0.75